Sorafenib in the treatment of advanced hepatocellular carcinoma

Saudi Journal of Gastroenterology

Volumn 14, Issue 1, 2008, Pages 40-42

  Mousa, Ali Ben ^a  

^a The General Directorate of Armed Forces Health Services   (Saudi Arabia)

Author keywords

Hepatocellular carcinoma; Kinase inhibitor; Sorafenib

Indexed keywords

EID: 38149084758     PISSN: 13193767     EISSN: None     Source Type: Journal    
DOI: 10.4103/1319-3767.37808     Document Type: Article

References (16)

1. Cancer Incidence Report in Saudi Aabia 2002. Available from: http://www.kfshrc.edu.sa/NCR
2. International Agency for Cancer Research. GLOBOCAN 2002. Available from: http://www-depi.arc.fr.
3. Awada A Hendlisz A Gil T, Bartholomeus S, Mano M, de Valeriola D, et al. Phase I safety and pharmacokinetics of BAY43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005;92:1855-61.
4. Sorafenib, product information. Available from: http://www.univgraph.com/ bayer/inserts/sorafenib.pdf.
5. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERKmitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007;26:3291-310.
6. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
7. Elser C, Siu LL, Winquist E, Agulnik M Pond GR, Chin SF, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007;25:3766-73.
8. Adjei AA, Molina JR, Mandrekar SJ, Marks R, Raid JR, Croghan G, et al. Phase I trial of sorafenib in combination with gefltinib in patients with refractory or recurrent non-small cell lung cancer, Clin Cancer Res 2007;13:2684-91.
9. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br J Dermatol 2007;156:1204-13.
10. Schneider BR Sledge GW Jr. Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol 2007;4:181-9.
11. Siu LL, Awada A, Takimoto CH, Piccart M, Schwartz B, Qannaris T, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an. expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006;12:144-51.
12. Liu Y Poon RT, Li Q, Kok TW, Lau C, Fan ST Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2005;65:3691-9.
13. Wiesenauer CA, Yip-Schneider MT, Wang Y Schmidt CM Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma. J Am Coll Surg 2004;198:410-21.
14. Abou-Alfa GK Schwartz L Ricci S, Anadori D, Santoro A Figer A et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300.
15. Llovet J, et al. Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial). Proceedings from the Anerican Society of Clinical Oncology Conference: Chicago, IL; 2007.
16. MacGregor JL Silvers DN, Grossman ME, Sherman WH Sorafenib-induced erythema multiforme. JAn Acad Dermatol 2007;56:527-8.